{'fraction_non_alphanumeric': 0.019193857965451054, 'fraction_numerical': 0.0019193857965451055, 'mean_word_length': 6.054054054054054, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre‐enfortumab vedotin era

Pembrolizumab, an anti‐PD‐1 monoclonal antibody, revolutionized the treatment for advanced urothelial carcinoma. However, the standard treatment for patients after disease progression with pembrolizumab had not been established until the recent approval of enfortumab vedotin. We analyzed the treatment of these patients in the real world, and the patient background and outcomes.